Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McKinsey’s Push For Class-Wide Opioid REMS Among Actions Targeted In Opioid Settlement

Executive Summary

Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.

You may also be interested in...



Will US FDA Change Its Conflict Of Interest Policies In Wake Of McKinsey’s Work With Purdue?

House Oversight Committee members grill McKinsey global managing partner about whether the firm told FDA about its simultaneous work for opioid maker Purdue. Agency says it does not anticipate future contracts with McKinsey until investigations are completed.

McKinsey's Overlapping Work For FDA, Opioid Makers Raises Conflict Of Interest Questions

A House Oversight and Reform Committee report says McKinsey consultants advised the FDA on modernization of its new drugs regulatory program, the Sentinel Initiative, and other projects at the same time it was working for opioid manufacturers on related topics; agency says McKinsey did not inform it of potential conflicts of interest.

Vaccine Technologies: US FDA Isn’t Afraid Of Needle-Free Delivery, But It Takes Time To Develop, Woodcock Says

The agency is interested in alternative formulations for COVID-19 inoculations, but pushed the traditional injection presentation because it was easier to develop quickly.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS143735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel